Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients requiring long term anticoagulation often undergo transition of their warfarin to heparin in anticipation of invasive surgical procedures such as pacemaker or ICD implantation. This may require inpatient hospitalization several days prior to and after the procedure, potentially increasing medical costs and patient inconvenience. Patients undergoing such a process are initiated on heparin while their INRs drift to normal levels. Immediately prior to surgery, heparin is discontinued and restarted several hours after the procedure. Unfortunately, this process has resulted in a high incidence of surgical wound hematomas and other bleeding complications often requiring longer periods of discontinued anticoagulation or repeat surgical exploration. Previous investigators have tried to reduce the incidence of wound hematomas by prolonging the time from surgical wound closure to the reinitiation of heparin. A small randomized trial demonstrated that there was no significant difference in the incidence of wound hematomas whether heparin was started 6 hours or 24 hours after surgery (J Am Coll Cardiology 2000;35:1915-8). This has led many investigators to perform pacemaker and ICD implantation without reversal of warfarin therapy. A recent retrospective observational study demonstrated that the incidence of wound hematomas in patients with an INR of 2.6 was no different than patients with an INR of 1.5 (PACE 2004;27:358-60). Furthermore, a more recent, larger retrospective observational study reported in abstract form at the recent Heart Rhythm Society Annual 2007 Scientific Meeting demonstrated that not only is performing pacemaker and ICD implantations safe without reversing warfarin anticoagulation, but the incidence of wound hematomas is significantly smaller as compared to the strategy of reversing warfarin and initiating periprocedural heparin.
Given these findings, the hypothesis of this randomized study is that pacemaker and ICD implantation while fully anticoagulated on warfarin therapy is safe. Findings from this study will have significant implications on the clinical practice of pacemaker or ICD implantation in this patient population given that no randomized study on this subject has been performed to date.
| Condition | Intervention |
|---|---|
|
Bradycardia Tachycardia Atrial Fibrillation Valvular Heart Disease |
Drug: continue warfarin through the procedure Drug: Hold warfarin Drug: Warfarin held with heparin transition. |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation |
- bleeding complication [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 104 |
| Study Start Date: | September 2007 |
| Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
|
Drug: continue warfarin through the procedure
The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
|
|
Active Comparator: 2
Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
|
Drug: Hold warfarin
For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
|
|
Experimental: 3
High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
|
Drug: continue warfarin through the procedure
The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
|
|
Active Comparator: 4
High risk patients randomized to holding coumadin for 4-5 days and using "bridging" anticoagulation with heparin while the coumadin is held.
|
Drug: Warfarin held with heparin transition.
For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- scheduled for clinically indicated permanent pacemaker or implantable cardioverter-defibrillator
- currently on chronic warfarin therapy
Exclusion Criteria:
- unwilling to participate in trial
Contacts and Locations| United States, Maryland | |
| Johns Hopkins Hospital | |
| Baltimore, Maryland, United States, 21205 | |
| Johns Hopkins Bayview Medical Center | |
| Baltimore, Maryland, United States, 21224 | |
| Howard County General Hospital | |
| Columbia, Maryland, United States, 21045 | |
| Principal Investigator: | Alan Cheng, MD | Johns Hopkins University |
More Information
No publications provided
| Responsible Party: | Charles Henrikson, MD - Cardiology/Medicine, Assistant Professor of Medicine, Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00721136 History of Changes |
| Other Study ID Numbers: | NA_00011273 |
| Study First Received: | July 21, 2008 |
| Last Updated: | October 2, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Johns Hopkins University:
|
bleeding anticoagulation pacemaker implantable cardioverter-defibrillator patients undergoing implantation of a pacemaker or defibrillator (ICD)" |
Additional relevant MeSH terms:
|
Atrial Fibrillation Heart Diseases Heart Valve Diseases Tachycardia Bradycardia Arrhythmias, Cardiac Cardiovascular Diseases Pathologic Processes Heparin |
Warfarin Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 16, 2013